Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems and computerized numerical control machines, milling heads, related software, and accessories.
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Fidia's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FDA has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: FDA underperformed the Italian Machinery industry which returned -7% over the past year.
Return vs Market: FDA underperformed the Italian Market which returned -6.7% over the past year.
Price Volatility Vs. Market
How volatile is Fidia's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StDo Insiders Own Lots Of Shares In Fidia S.p.A. (BIT:FDA)?
4 months ago | Simply Wall StA Look At The Intrinsic Value Of Fidia S.p.A. (BIT:FDA)
4 months ago | Simply Wall StSome Fidia (BIT:FDA) Shareholders Have Copped A Big 64% Share Price Drop
Is Fidia undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: FDA (€2.66) is trading above our estimate of fair value (€0.11)
Significantly Below Fair Value: FDA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: FDA is unprofitable, so we can't compare its PE Ratio to the IT Machinery industry average.
PE vs Market: FDA is unprofitable, so we can't compare its PE Ratio to the Italian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FDA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FDA is overvalued based on its PB Ratio (3.1x) compared to the IT Machinery industry average (1.2x).
How is Fidia forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FDA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FDA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FDA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FDA's revenue is expected to decline over the next 3 years (-11.1% per year).
High Growth Revenue: FDA's revenue is forecast to decline over the next 3 years (-11.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FDA's Return on Equity is forecast to be high in 3 years time
How has Fidia performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FDA is currently unprofitable.
Growing Profit Margin: FDA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FDA is unprofitable, and losses have increased over the past 5 years at a rate of 62.7% per year.
Accelerating Growth: Unable to compare FDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FDA is unprofitable, making it difficult to compare its past year earnings growth to the Machinery industry (-30.7%).
Return on Equity
High ROE: FDA has a negative Return on Equity (-75.8%), as it is currently unprofitable.
How is Fidia's financial position?
Financial Position Analysis
Short Term Liabilities: FDA's short term assets (€29.0M) exceed its short term liabilities (€29.0M).
Long Term Liabilities: FDA's short term assets (€29.0M) exceed its long term liabilities (€11.3M).
Debt to Equity History and Analysis
Debt Level: FDA's debt to equity ratio (137.8%) is considered high.
Reducing Debt: FDA's debt to equity ratio has increased from 26.4% to 137.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable FDA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: FDA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 1% per year.
What is Fidia current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FDA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FDA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: FDA is not paying a notable dividend for the Italian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FDA's dividend in 3 years as they are not forecast to pay a notable one for the Italian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Giuseppe Morfino (76 yo)
Engineer Giuseppe Morfino has been the Chairman and CEO of Fidia S.p.A. since April 28, 2017. He serves as the President and Managing Director at Fidia Spa. Engineer Morfino serves as General Manager at Fi ...
CEO Compensation Analysis
Compensation vs Market: Giuseppe's total compensation ($USD0.00) is below average for companies of similar size in the Italian market ($USD455.32K).
Compensation vs Earnings: Giuseppe's compensation has been consistent with company performance over the past year.
|Director of Financial Reporting & Director||3.33yrs||€17.65k||no data|
|Independent Director||3.33yrs||no data||no data|
|Independent Director||2.33yrs||no data||no data|
|Statutory Auditor||0.58yr||no data||no data|
|Vice President of the Board||0.58yr||no data||no data|
|President of Statutory Auditor||0.58yr||no data||no data|
|Statutory Auditor||0.58yr||no data||no data|
Experienced Board: FDA's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Fidia S.p.A.'s company bio, employee growth, exchange listings and data sources
- Name: Fidia S.p.A.
- Ticker: FDA
- Exchange: BIT
- Founded: 1974
- Industry: Industrial Machinery
- Sector: Capital Goods
- Market Cap: €13.601m
- Shares outstanding: 5.11m
- Website: https://www.fidia.it
Number of Employees
- Fidia S.p.A.
- Corso Lombardia, 11
- San Mauro Torinese
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FDA||BIT (Borsa Italiana)||Yes||Common Stock||IT||EUR||Nov 2000|
|0EFO||LSE (London Stock Exchange)||Yes||Common Stock||GB||EUR||Nov 2000|
|FDAM||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Stock||GB||EUR||Nov 2000|
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems and computerized numerical control machines, milling heads, related software, and accessories. The ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/06 21:23|
|End of Day Share Price||2020/08/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.